Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 1/20 | 0.52 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.47 |
| ▸ | P2RY1 | P47900 | 14/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.43 |
| ▸ | GOT1 | P17174 | 1/20 | 0.43 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | IGF1R | P08069 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15054194 | 0.92 | NTRK1 (0.43) | NTRK1STING1P2RY1TRPV1 | |
| SCHEMBL3703952 | 0.92 | NTRK1 (0.53) | NTRK1STING1P2RY1NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL3705741 | 0.91 | NTRK1 (0.53) | NTRK1STING1P2RY1NPC1RAB9A | |
| SCHEMBL15053108 | 0.90 | SMN1; SMN2 (0.48) | NTRK1P2RY1NPC1RAB9ATRPV1 | |
| SCHEMBL15052996 | 0.90 | BRAF (0.50) | NTRK1STING1P2RY1GOT1TRPV1 | |
| SCHEMBL15053102 | 0.89 | KDR (0.44) | NTRK1STING1P2RY1NPC1RAB9A | |
| SCHEMBL15052778 | 0.89 | NTRK1 (0.40) | NTRK1STING1P2RY1P2RY14P2RY2 | |
| SCHEMBL15053586 | 0.88 | RAB9A (0.44) | NTRK1STING1P2RY1NPC1RAB9A | |
| SCHEMBL15053584 | 0.88 | MAPT (0.42) | NTRK1P2RY1NPC1RAB9ATRPV1 | |
| SCHEMBL15052682 | 0.87 | MAPT (0.43) | TRPV1IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165475-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ASCEPION PHARMACEUTICALS, INC. (CN) | 2013-06-27 | — | — | US | claimed |
| US-20130165475-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ASCEPION PHARMACEUTICALS, INC. (CN) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165475-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK2, CDK1, CDK3 | NTRK1 1407/4885STING1 2889/4885P2RY1 3772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.